Finerenone is a non-steroidal mineralocorticoid receptor antagonist used as an active pharmaceutical ingredient. It is supplied as a pharmaceutical raw material for the manufacturing of medications indicated to reduce the risk of kidney function decline, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes, as well as for heart failure with reduced ejection fraction.
Escopo do conteúdo: As informações desta página dizem respeito à identificação química e aos contextos de fornecimento industrial, pesquisa e produção. Não constituem alegação terapêutica, aconselhamento médico ou instruções de uso de medicamentos.
Adquirindo ou fornecendo este composto?
Publique seu inventário ou uma solicitação de compra
CAS 1050477-27-4
4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid
pharmaceutical intermediate for finerenone
(S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylic Acid
Pharmaceutical intermediate for finerenone
(4R)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxylic acid
n.a
5-Desethoxy,-5-Methoxy-Finerenone
Mineralocorticoid receptor antagonist intermediate
Dolutegravir
HIV-1 integrase inhibitor
DOLUTEGRAVIR SODIUM
active pharmaceutical ingredient
7-methyl-2-(2,2,3,3-tetradeuteriocyclopropyl)-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
active pharmaceutical ingredient
Tetrabutylammonium acetate
Phase transfer catalyst
4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
BTBHLEZXCOBLCY-UHFFFAOYSA-N
CCOC1=NC=C(C2=C1C(C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C